KRN 8602

Drug Profile

KRN 8602

Alternative Names: MX 2; NSC 619003

Latest Information Update: 11 Jul 2007

Price : $50

At a glance

  • Originator Kirin Brewery
  • Developer Kirin Holdings Company
  • Class Anthracyclines; Cytostatic antibiotics
  • Mechanism of Action DNA inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • No development reported Acute lymphoblastic leukaemia; Acute myeloid leukaemia; Brain cancer; Breast cancer

Most Recent Events

  • 17 Feb 2000 A clinical study in glioma has been added to the therapeutic trials section
  • 25 Aug 1999 A study has been added to the therapeutic trials and adverse events sections
  • 26 Jul 1999 Phase-II clinical trials for Acute lymphoblastic leukaemia in Japan (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top